L01DB06 • idarubicin • Antineoplastic and immunomodulating agents | Cytotoxic antibiotics and related substances | Anthracyclines and related substances
Idarubicin is a chemotherapy drug used for the treatment of acute leukemia, including acute myeloid leukemia (AML). It belongs to the anthracycline class and works by inhibiting DNA synthesis in cancer cells, thereby preventing cell division.
The medication is administered intravenously, as directed by a doctor. It is important to monitor the patient for adverse effects during treatment.
Side effects may include nausea, vomiting, hair loss, bone marrow suppression, or cardiac toxicity. In rare cases, severe allergic reactions may occur.
Idarubicin is not recommended for patients with severe cardiac insufficiency, severe bone marrow suppression, or hypersensitivity to anthracyclines.
Substance: idarubicin
Date of last drug list: 01-06-2025
Commercial code: W65096001
Concentration: 5mg
Pharmaceutical form: powder for injection
Quantity: 1
Product type: original
Price: 147.45 RON
Prescription restrictions: P-RF - Medicines prescription that is retained in the pharmacy (not renewable).
Manufacturer: CORDEN PHARMA LATINA S.P.A. - ITALIA
Holder: PFIZER EUROPE MA EEIG - BELGIA
Number: 11181/2018/01
Shelf life: 2 years-after packing for marketing;after reconstituting the solution-it is used immediately